Seguir
Tao He
Tao He
JOINN Biologics
Dirección de correo verificada de joinnbio.com
Título
Citado por
Citado por
Año
Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy
LN Tumey, M Charati, T He, E Sousa, D Ma, X Han, T Clark, J Casavant, ...
Bioconjugate chemistry 25 (10), 1871-1880, 2014
1942014
Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery
DD Fang, YJ Kim, CN Lee, S Aggarwal, K McKinnon, D Mesmer, J Norton, ...
British journal of cancer 102 (8), 1265-1275, 2010
1772010
Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients
GR Nicol, M Han, J Kim, CE Birse, E Brand, A Nguyen, M Mesri, ...
Molecular & Cellular Proteomics 7 (10), 1974-1982, 2008
1392008
Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer
AR Root, W Cao, B Li, P LaPan, C Meade, J Sanford, M Jin, C O’Sullivan, ...
Antibodies 5 (1), 6, 2016
942016
GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates
DM Breen, H Kim, D Bennett, RA Calle, S Collins, RM Esquejo, T He, ...
Cell metabolism 32 (6), 938-950. e6, 2020
812020
Lung disease targets and uses thereof
B Domon, E Joseloff, A Li, T He
US Patent 7,807,392, 2010
652010
Breast disease targets and uses thereof
J Heidbrink, S Ruben, CE Birse, T He
US Patent 7,842,467, 2010
642010
Quantitation of phosphopeptides using affinity chromatography and stable isotope labeling
T He, K Alving, B Feild, J Norton, EG Joseloff, SD Patterson, B Domon
Journal of the American Society for Mass Spectrometry 15 (3), 363-373, 2004
622004
Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium
CE Birse, RJ Lagier, W FitzHugh, HI Pass, WN Rom, ES Edell, ...
Clinical proteomics 12, 1-12, 2015
542015
Kidney disease targets and uses thereof
E Joseloff, S Ruben, T He, YJ Kim
US Patent 7,608,413, 2009
532009
Integrating titania enrichment, iTRAQ labeling, and Orbitrap CID‐HCD for global identification and quantitative analysis of phosphopeptides
J Wu, P Warren, Q Shakey, E Sousa, A Hill, TE Ryan, T He
Proteomics 10 (11), 2224-2234, 2010
462010
Kidney disease targets and uses thereof
E Joseloff, S Ruben, T He, Y Kim
US Patent App. 13/183,696, 2012
432012
Reproducibility Assessment of Relative Quantitation Strategies for LC− MS Based Proteomics
YJ Kim, P Zhan, B Feild, SM Ruben, T He
Analytical chemistry 79 (15), 5651-5658, 2007
422007
Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues
M Mesri, C Birse, J Heidbrink, K McKinnon, E Brand, CL Bermingham, ...
PLoS One 8 (11), e78885, 2013
392013
Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer
S Aggarwal, T He, W FitzHugh, K Rosenthal, B Feild, J Heidbrink, ...
Gynecologic oncology 115 (3), 430-437, 2009
372009
Detection of CXADR protein for diagnosis of kidney cancer
E Joseloff, S Ruben, T He, Y Kim
US Patent 7,998,689, 2011
332011
Lung disease targets and uses thereof
E Joseloff, A Li, T He, S Ruben
US Patent App. 12/400,212, 2009
332009
Colon disease targets and uses thereof
Y Kim, T He, S Ruben
US Patent 7,842,466, 2010
262010
Glyco-engineered long acting FGF21 variant with optimal pharmaceutical and pharmacokinetic properties to enable weekly to twice monthly subcutaneous dosing
Y Weng, T Ishino, A Sievers, S Talukdar, JR Chabot, A Tam, W Duan, ...
Scientific Reports 8 (1), 4241, 2018
232018
Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions
X Zhong, E Kieras, E Sousa, A D'Antona, JC Baber, T He, J Desharnais, ...
Journal of Biological Chemistry 288 (2), 1409-1419, 2013
212013
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20